ArticleAsia Pacific journal of clinical nutrition2025
Dietary inflammatory index and blood inflammatory markers in relation to dyslipidemia: A cross-sectional NHANES study (2009-2018).
Article in Asia Pacific journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.Kidney international reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe presence and accumulation of inflammation may exacerbate the develop-ment of dyslipidemia. Therefore, this study aimed to explore the relationship between blood inflammatory markers and the dietary inflammatory index (DII) in American adults as well as their association with dyslipidemia. METHODS AND STUDY
designThis cross-sectional study included participants with complete data on lipid levels, dietary intake, and blood inflammatory markers. The associations between dyslipidemia and two sets of exposures-blood inflammatory markers and the DII-were analysed using weighted univariate and multivariate logistic regression models.
resultsAmong the 9,441 participants (2009-2018), 6,689 (70.9%) had dyslipidemia. Logistic regression analysis revealed that higher DII quartiles were significantly associated with an increased risk of dyslipidemia, with the fourth quartile exhibiting an odds ratio of 1.33 (95% CI: 1.10-1.62; p < 0.001). Furthermore, DII combined with various blood inflammatory markers was consistently associated with an increased dyslipidemia risk (all OR > 1.0, all p < 0.05). A non-linear relationship was observed between the systemic immune-inflammation index (SII) and dyslipidemia risk, which became significant when the SII exceeded 434.65.
conclusionsDII and blood inflammation markers showed a positive association with dyslipidemia. Nonetheless, these findings still offer valuable insights to public health policymakers for developing evidence-based strategies to prevent dyslipidemia and potentially reduce inflammation-associated dyslipidemia risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.